Your browser doesn't support javascript.
loading
Effect of mobile-based cognitive behavior therapy (CBT) on lowering of blood lipid levels in atherosclerotic cardiovascular disease (ASCVD) patients: study protocol for a multicenter, prospective, randomized controlled trial.
Hong, Xu-Lin; Luan, Yi; Liu, Hong-Ying; Zhang, Wen-Bin.
Afiliación
  • Hong XL; Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
  • Luan Y; Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
  • Liu HY; Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
  • Zhang WB; Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. 3313011@zju.EDU.CN.
Trials ; 23(1): 543, 2022 Jun 30.
Article en En | MEDLINE | ID: mdl-35773718
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains a major source of mortality in China. Convincing evidence has demonstrated that the reduction of low-density lipoprotein cholesterol (LDL-C) is correlated with lowering ASCVD risk. The efficacy of lifestyle management in lipid levels reduction has been confirmed in numerous studies. However, considering that low compliance to lifestyle management has limited the benefits of lowering lipid levels, cognitive behavior therapy (CBT) is proposed as a solution to improve clinical outcomes. The objective of this trial is to compare the LDL-C outcome in ASCVD patients receiving mobile device-based CBT to a control group, with both groups under standard pharmacological treatments. METHODS: This trial is designed as a multicenter, prospective randomized controlled trial with a 6-month follow-up. Mean LDL-C level and the percentage of different LDL-C levels, coefficient of variation of LDL, General Self-Efficacy Scale (GSEs), quality of life index (QL-index), etc., between the two groups at baseline, 1, 3, and 6 months will be measured. DISCUSSION: This trial should demonstrate that the implementation of mobile-based CBT intervention will be potentially effective in lowering LDL-C levels in ASCVD patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( ChiCTR2100046775 ) [registered: 2021/5/28].
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Terapia Cognitivo-Conductual / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Terapia Cognitivo-Conductual / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido